Informations générales (source: ClinicalTrials.gov)
A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventional
Phase 1
Johnson & Johnson Enterprise Innovation Inc. (Voir sur ClinicalTrials)
janvier 2026
juillet 2028
07 juin 2026
This global, open-label, single arm, phase 1b study aims to learn more about whether a
treatment called JNJ-90301900 is safe and effective when injected directly into tumors,
along with standard chemotherapy and radiation therapy, for participants with head and
neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer
of the mouth & throat).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | France NGUYEN | 09/06/2026 18:00:08 | Contacter | ||
Critères
Tous
- Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the
oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
- Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee
on Cancer (AJCC) guidelines
- A candidate for definitive concurrent chemoradiation therapy treatment as determined
by investigator and per local guidelines
- Participants must have at least 1 target lesion (primary tumor or involved lymph
node) per RECIST v.1.1
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
Exclusion criteria:
- Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands,
thyroid gland, parathyroid gland, skin, or unknown primary site
- Non-squamous histology
- Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous
second primary HNSCC (within 2 months)
- Ineligible to receive cisplatin chemotherapy
- Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or
its excipients